| Name | Afuresertib |
| Description | Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. |
| Cell Research | A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0-30 μM. Cell growth is determined relative to untreated (DMSO) controls. EC50's are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application.(Only for Reference) |
| Kinase Assay | Potency (Ki*) of afuresertib: The true potency (Ki*) of the inhibitor is initially determined at low enzyme concentrations (0.1 nM AKT1, 0.7 nM AKT2, and 0.2 nM AKT3) using a filter binding assay and then confirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor is incubated for 1 h and then added to a GSKα peptide (Ac-KKGGRARTSS-FAEPG-amide) and [γ33P] ATP. Reactions are terminated after 2 h and the radio labeled AKT peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilizes continuous real-time fluorescence detection of product formation using the Sox-AKT-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2). |
| In vitro | Overall 65% of hematological cell lines were sensitive to Afuresertib with an EC50 < 1 μM. 21% of solid tumor cell lines tested had an EC50 < 1 μM for Afuresertib. Afuresertib inhibited the kinase activity of the E17K AKT1 mutant protein with an EC50 of 0.2 nM. Afuresertib showed Afuresertib showed a concentration-dependent effect on the phosphorylation levels of multiple AKT substrates, including GSK3b, PRAS40, FOXO and cystatin 9. |
| In vivo | Overall 65% of hematological cell lines were sensitive to Afuresertib with an EC50 < 1 μM. 21% of solid tumor cell lines tested had an EC50 < 1 μM for Afuresertib. Afuresertib inhibited the kinase activity of the E17K AKT1 mutant protein with an EC50 of 0.2 nM. Afuresertib showed Afuresertib showed a concentration-dependent effect on the phosphorylation levels of multiple AKT substrates, including GSK3b, PRAS40, FOXO and cystatin 9. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (117.01 mM)
Ethanol : 79 mg/mL (184.9 mM)
|
| Keywords | ROK | Rho-associated kinase | Rho-kinase | Inhibitor | Rho-associated protein kinase | Akt | GSK-2110183 | inhibit | PKC | PKB | GSK 2110183 | Protein kinase C | Afuresertib | ROCK | Protein kinase B |
| Inhibitors Related | Ethyl gallate | Darovasertib | α-Vitamin E | Staurosporine | RKI-1447 | Artemisinin | Honokiol | Y-27632 dihydrochloride | Mitoxantrone dihydrochloride | 2,3-Butanediol | Y-27632 | Thiazovivin |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
